References | CAYSTON® (aztreonam for inhalation solution)

  1. Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002;34(2):91-100.

  2. Cystic Fibrosis Foundation. 2019 Patient Registry Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation; 2019. Accessed January 12, 2022. https://www.cff.org/sites/default/files/2021-10/2019-Patient-Registry-Annual-Data-Report.pdf

  3. Pseudomonas. Cystic Fibrosis Foundation website. Accessed January 12, 2022. https://www.cff.org/managing-cf/pseudomonas

  4. Cystic fibrosis. US National Library of Medicine website. Updated August 18, 2020. Accessed April 14, 2021. https://medlineplus.gov/genetics/condition/cystic-fibrosis/

  5. Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013;187(7):680-689.

  6. Pritt B, O’Brien L, Winn W. Mucoid Pseudomonas in cystic fibrosis. Am J Clin Pathol. 2007;128(1): 32-34.

  7. Basics of lung care. Cystic Fibrosis Foundation website. Accessed January 12, 2022. https://www.cff.org/basics-lung-care

  8. Cunningham JC, Taussig LM. Respiratory System. In: An Introduction to Cystic Fibrosis: For Patients and Their Families. 6th ed. Cystic Fibrosis Foundation; 2013:41-58.

  9. Starner TD, McCray PB. Pathogenesis of Early Lung Disease in Cystic Fibrosis: A Window of Opportunity to Eradicate Bacteria. Ann Intern Med. 2005;143(11):816-822.

  10. Li Z, Kosorok MR, Farrell PM, et al. Longitudinal Development of Mucoid Pseudomonas aeruginosa Infection and Lung Disease Progression in Children With Cystic Fibrosis. JAMA. 2005; 293(5):581-588.

  11. Kriengkauykiat J, Benitez D, Beringer P. Bacteria and Antibiotic Resistance in People With Cystic Fibrosis. Cystic Fibrosis Foundation; University of Southern California. Accessed January 12, 2022. https://intmed.vcu.edu/media/intmed-dev/cf/cf-documents/cf-documents/bacteria_antibiotic_resistance.pdf

  12. Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest. 2009;135(5):1223-1232.

  13. Assael BM, Pressler T, Bilton D, et al. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. J Cyst Fibros. 2013;12(2):130-140.

  14. Lee TW, Brownlee KG, Conway SP, Denton M, Littlewood JM. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros. 2003;2(1):29-34.

  15. CF care center visits. Cystic Fibrosis Foundation website. Accessed September 23, 2021. https://www.cff.org/managing-cf/cf-care-center-visits

  16. Maintaining healthy weight with Cystic Fibrosis. Cystic Fibrosis Foundation website. Accessed September 16, 2021. https://www.cff.org/sites/default/files/2021-10/Maintaining-Healthy-Weight-With-Cystic-Fibrosis.pdf

  17. New South Wales Ministry of Health. Sputum induction guidelines. NSW Government Health. Accessed September 23, 2021. https://www.health.nsw.gov.au/Infectious/tuberculosis/Pages/tb-sputum-induction-guidelines.aspx

  18. Yen EH, Quinton H, Borowitz D. Better nutritional status in early childhood is associated with improved clinical outcomes and survival in patients with cystic fibrosis. J Pediatr. 2013;162(3):530-535.